COMP <GO>
VRTX vs UNH // NET PROFIT MARGIN
Vertex Pharmaceuticals Incorporated (NASDAQ) VS. UnitedHealth Group Incorporated (NYSE) • 15-METRIC TALLY: VRTX 8
— UNH 7
▲ NET PROFIT MARGIN LEADER: VRTX
LAST: $558.88 (+3.50%) • MKT CAP: $136.87B
net-margins
32.90%
LAST: $406.97 (-0.96%) • MKT CAP: $364.66B
net-margins
3.14%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VRTX VS. UNH)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VRTX | UNH | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 86.20% | 88.57% | -2.37 | UNH | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 20.00% | 11.47% | +8.53 | VRTX | /roic <GO> |
| EV/EBITDA & P/E Valuation | 29.6x | 16.4x | +13.15 | UNH | /valuation <GO> |
| Free Cash Flow Yield | 2.33% | 6.48% | -4.15 | UNH | /fcf-yield <GO> |
| Operating Margin | 34.80% | 4.82% | +29.98 | VRTX | /operating-margins <GO> |
| Net Profit Margin ACTIVE | 32.90% | 3.14% | +29.76 | VRTX | /net-margins <GO> |
| Revenue Growth (YoY) | 8.90% | 6.46% | +2.44 | VRTX | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.28% | -2.28 | UNH | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 13.86 | 3.12 | +10.74 | VRTX | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | VRTX | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | 7.00% | 6.74% | +0.26 | UNH | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 67.7 | 56.0 | +11.60 | VRTX | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.02 | 0.33 | +0.69 | VRTX | /macro-sensitivity <GO> |
| Forward P/E Multiple | 32.2x | 17.1x | +15.11 | UNH | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $136.87B | $364.66B | -$227.79B | UNH | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VRTX REV | UNH REV | VRTX GROSS % | UNH GROSS % | VRTX FCF | UNH FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $12.00B | $447.57B | 86.2% | 88.7% | $3.19B | $16.07B |
| FY 2024 | $11.02B | $400.28B | 86.1% | 88.3% | -$790.3M | $20.70B |
| FY 2023 | $9.87B | $371.62B | 44.0% | 89.6% | $3.09B | $25.68B |
| FY 2022 | — | $324.16B | — | 89.6% | — | $23.40B |
| FY 2021 | — | $287.60B | — | 89.2% | — | $19.89B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VRTX // BETA 1.02
UNH // BETA 0.33